Step 1 topics → Hematology and Oncology → Myelodysplastic Syndrome

Myelodysplastic Syndrome

USMLE Step 1 trap: Confuses MDS marrow cellularity (hypercellular with dysplasia) with aplastic anemia (hypocellular). MDS typically presents with a hypercellular or normocellular marrow with dysplastic (morphologically abnormal) cells, distinguishing it from the hypocellular marrow of aplastic anemia.

Myelodysplastic syndrome (MDS) is a clonal stem cell disorder where hematopoietic precursors proliferate but mature abnormally — the marrow is busy but incompetent, producing cells that don't work or die before leaving. USMLE Step 1 tests this paradox directly: peripheral cytopenias despite a hypercellular marrow. The most common wrong answer is aplastic anemia — students see cytopenias and assume an empty marrow, but in MDS the marrow is full of dysplastic precursors that die intramedullary before reaching the blood. Lock in that distinction before anything else on this topic.

The exam tests MDS from two main angles: morphologic recognition and clinical context. On the morphology side, you need to recognize pseudo Pelger-Huet cells (bilobed neutrophils with clumped chromatin), hypersegmented or hyposegmented forms, and ring sideroblasts on Prussian blue stain as flags for specific subtypes. On the clinical side, Step 1 wants you to know when MDS arises — particularly after alkylating agent chemotherapy or radiation — and how to think about progression risk. The 5q- deletion is a classic cytogenetic marker associated with a favorable prognosis subtype and is a recurring vignette hook.

The trickiest part of MDS is distinguishing it from conditions that superficially look similar. Students frequently confuse MDS with aplastic anemia because both cause cytopenias, but the marrow findings are opposite. Students also tend to overestimate AML transformation — MDS is not a guaranteed leukemia pipeline. Many patients die from infection or bleeding due to cytopenias long before any transformation occurs. Keeping these distinctions crisp is what separates a medium-tier correct answer from a trap.

From real student decks
59%have cards covering this topic
35%have mature cards
1.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: MDS presents with a hypocellular marrow like aplastic anemia because both cause cytopenias.
Right: MDS typically presents with a hypercellular or normocellular marrow with dysplastic (morphologically abnormal) cells, distinguishing it from the hypocellular marrow of aplastic anemia.
Both MDS and aplastic anemia produce cytopenias, but the bone marrow tells the opposite story. In aplastic anemia, the marrow is hypocellular — the stem cells are destroyed or absent. In MDS, the marrow is typically hypercellular or normocellular because dysplastic precursors are proliferating; they just can't mature properly, so they die intramedullary (ineffective hematopoiesis). On a Step 1 vignette, the bone marrow biopsy result is your critical differentiator: 'hypercellular with dysplastic forms' points to MDS, not aplastic anemia.
Common mistake
Gap: Missing ring sideroblasts as a characteristic morphologic finding in a MDS subtype
Ring sideroblasts (erythroblasts with iron-laden mitochondria encircling the nucleus) on Prussian blue stain are a key morphologic clue to MDS with ring sideroblasts subtype.
Ring sideroblasts are erythroblasts where iron-laden mitochondria accumulate in a ring around the nucleus — visible on Prussian blue stain as a perinuclear halo of blue granules. They indicate dysfunctional mitochondrial iron metabolism in erythroid precursors and define the MDS with ring sideroblasts subtype. If a vignette shows an elderly patient with macrocytic anemia and Prussian blue stain findings, ring sideroblasts should immediately flag MDS rather than a nutritional deficiency.
Common mistake
Wrong: All MDS cases inevitably and rapidly transform to AML.
Right: AML transformation occurs in approximately 30% of MDS cases overall, with risk varying by subtype and cytogenetics; many patients die of cytopenias rather than transformation.
AML transformation is a real risk in MDS but is neither inevitable nor rapid in all cases. Overall, only about 30% of MDS cases transform to AML, and this varies widely by subtype and karyotype — 5q- syndrome has a low transformation risk, while high-grade subtypes with complex cytogenetics transform more frequently. Critically, many MDS patients never see AML; they die from neutropenic infections or hemorrhage due to their cytopenias. Framing MDS as 'pre-leukemia' that always progresses overstates the biology and will lead you to wrong answers about prognosis.
Common mistake
Gap: Missing prior alkylating agent exposure as a key cause of secondary MDS with poor prognosis
Prior alkylating agent chemotherapy or radiation therapy is a major etiologic risk factor for secondary MDS, which carries a worse prognosis than de novo MDS.
Therapy-related MDS is a well-established complication of prior alkylating agent chemotherapy (e.g., cyclophosphamide, melphalan) or radiation therapy, typically appearing 5–10 years after exposure. This secondary MDS carries a significantly worse prognosis than de novo MDS because it often presents with complex cytogenetics and responds poorly to treatment. On Step 1, any cancer survivor — especially one treated for lymphoma, breast cancer, or multiple myeloma — who develops new unexplained cytopenias years later should prompt consideration of therapy-related MDS.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand how clonal dysplastic hematopoiesis produces peripheral cytopenias despite a hypercellular marrow, and be able to recognize the key abnormal cell morphologies (pseudo Pelger-Huet cells, ring sideroblasts, hypogranular neutrophils) that identify MDS on a bone marrow biopsy or smear.
  2. Know the risk of AML transformation in MDS — approximately 30% overall, not universal — and understand that subtype and cytogenetics (e.g., 5q- deletion as favorable, complex karyotype as unfavorable) determine prognosis; many patients die from cytopenia complications rather than leukemic transformation.
  3. Recognize prior alkylating agent chemotherapy or radiation as a major cause of secondary (therapy-related) MDS, which carries a worse prognosis than de novo MDS and is a classic setup in vignettes featuring cancer survivors presenting with new cytopenias.

Can you avoid these mistakes?

A 70-year-old man presents with fatigue and macrocytic anemia. Bone marrow biopsy shows a hypercellular marrow with hypolobated neutrophil precursors and erythroid precursors with iron-encircling-nucleus granules on Prussian blue stain. What is the diagnosis, and what specific morphologic finding on the stain is being described?
Why does a patient with MDS have peripheral cytopenias despite a bone marrow biopsy that shows increased cellularity? What is the term for this process?
A 58-year-old woman treated with melphalan for multiple myeloma 7 years ago now presents with pancytopenia. Bone marrow biopsy shows dysplastic forms. How does the etiology of her MDS affect her prognosis compared to a patient who developed MDS without prior chemotherapy?
An attending tells you that a patient's MDS 'will definitely turn into leukemia.' What is the actual AML transformation rate in MDS overall, and what factors determine whether a specific patient is at higher or lower risk of transformation?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →